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Abstract
Alterations in checkpoint and DNA repair pathways may provide adaptive mechanisms contributing to acquired drug
resistance. Here, we investigated the levels of proteins mediating DNA damage signaling and -repair in RPMI8226 multiple
myeloma cells and its Melphalan-resistant derivative 8226-LR5. We observed markedly reduced steady-state levels of DNA
glycosylases UNG2, NEIL1 and MPG in the resistant cells and cross-resistance to agents inducing their respective DNA base
lesions. Conversely, repair of alkali-labile sites was apparently enhanced in the resistant cells, as substantiated by alkaline
comet assay, autoribosylation of PARP-1, and increased sensitivity to PARP-1 inhibition by 4-AN or KU58684. Reduced base-
excision and enhanced single-strand break repair would both contribute to the observed reduction in genomic alkali-labile
sites, which could jeopardize productive processing of the more cytotoxic Melphalan-induced interstrand DNA crosslinks
(ICLs). Furthermore, we found a marked upregulation of proteins in the non-homologous end-joining (NHEJ) pathway of
double-strand break (DSB) repair, likely contributing to the observed increase in DSB repair kinetics in the resistant cells.
Finally, we observed apparent upregulation of ATR-signaling and downregulation of ATM-signaling in the resistant cells.
This was accompanied by markedly increased sensitivity towards Melphalan in the presence of ATR-, DNA-PK, or CHK1/2
inhibitors whereas no sensitizing effect was observed subsequent to ATM inhibition, suggesting that replication blocking
lesions are primary triggers of the DNA damage response in the Melphalan resistant cells. In conclusion, Melphalan
resistance is apparently contributed by modulation of the DNA damage response at multiple levels, including
downregulation of specific repair pathways to avoid repair intermediates that could impair efficient processing of
cytotoxic ICLs and ICL-induced DSBs. This study has revealed several novel candidate biomarkers for Melphalan sensitivity
that will be included in targeted quantitation studies in larger patient cohorts to validate their value in prognosis as well as
targets for replacement- or adjuvant therapies.
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Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy
characterized by abnormal proliferation of malignant plasma cells
in the bone marrow, leading to impaired hematopoiesis as well as
osteolytic bone destruction [1]. As a consequence, MM patients
often experience bone pain, bone fractures, hypercalcemia and
fatigue. In addition, MM cells produce excessive amounts of non-
functional antibodies, which mediate increased susceptibility to
infections. MM is the second most prevalent haematological
malignancy (approximately 10%) following non-Hodgkin’s lym-
phoma and constitute about 1% of all malignancies. It is also
showing substantial and systematic mortality (1% of total cancer
deaths) in the elderly of most areas worldwide [1,2].
Since its introduction in 1958, Melphalan (L-phenylalanine
mustard, Alkeran, CAS 148-82-3) [3] has been a common agent to
treat MM. In combination with prednisone (MP) it has been the
core treatment for patients with newly diagnosed MM who are not
eligible for autologous stem cell transplant (ASCT) and is also
central in high dose therapy (HDM) prior to ASCT [4,5]. More
recently, MP has also been combined with novel agents such as
thalidomide, lenalidomide and bortezomib in patients not eligible
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for ASCT [6] and this has increased survival ([7] and references
therein). Although the initial response to Melphalan-based
treatment is generally good, treatment is limited by development
of acquired drug resistance (ADR) [8] and eventually all cases
become refractive [6]. There is thus an urgent need to develop
means for early detection of ADR to improve prognosis and
treatment.
Melphalan is a bifunctional alkylating agent belonging to the
nitrogen mustard class of chemotherapeutic agents, and induces
both DNA monoadducts and ICLs [9,10]. Although ICLs
apparently constitute a minor fraction of the DNA lesions
introduced by Melphalan [11,12] they have been regarded the
major cytotoxic lesions since they block DNA replication and
induce the formation of DNA double-strand breaks (DSBs) [9].
Modulation of several cellular processes have been suggested to
contribute to resistance, including reduced drug uptake due to
defective drug transport [13], elevated glutathione levels [14,15],
decreased apoptosis [16,17] and modulated interaction of the
myeloma cells with extracellular matrix [18]. More recently,
modulation of DNA damage signaling- and repair pathways have
also been suggested to be major contributors to Melphalan
resistance [19–21]. This work has primarily focused upon the role
of the Fanconi Anemia (FA)/BRCA1 pathway in enhancing ICL
repair, thereby promoting cell survival [17,21–24]. However,
Melphalan may form a number of different adducts in DNA,
including (but likely not limited to) intra- and interstrand guanine
N7 crosslinks, adenine N3 alkylations and DNA-protein crosslinks
[25,26]. Moreover, a marked elevation of oxidative stress markers
has been observed in patients undergoing MP-based conditioning
regimen prior to ACST, as well as subsequent to transplant [27]
suggesting that oxidative DNA damage may also contribute to
cytotoxicity. The quantitative contribution of each type of DNA
lesion to Melphalan cytotoxicity remains, however, to be
established.
Repair of ICLs is not yet fully understood. However, proteins
belonging to several different DNA repair pathways cooperate to
resolve these complex lesions, including proteins contributing to
the FA-pathway, nucleotide excision repair (NER), mismatch
repair (MMR) and double-strand break repair (DSBR) ([28] and
references therein). More recently, the involvement of base
excision repair (BER) in development of resistance to DNA
crosslinkers has been increasingly recognized [29,30]. Interesting-
ly, while enhanced BER activities mediate resistance against
antitumor agents in some types of cancer [31–33], BER deficiency
has also been connected with development of Cisplatin resistance
[34]. To gain more insight into potential contribution to
Melphalan resistance by proteins involved in DNA damage
signaling and repair, we investigated the expression of a broad
panel of proteins involved in the DNA damage response in the
Melphalan-sensitive multiple myeloma cell line RPMI8226 and its
Melphalan resistant derivative 8226-LR5. Interestingly, our
findings demonstrate that expression of several factors not
previously associated with Melphalan resistance is altered in the
resistant cells. Specifically we observed a striking downregulation
of several DNA glycosylases in the resistant cells in parallel with
apparently increased efficiency of single- (SSB) and double strand
break (DSB) repair. This suggest that resistant cells modulate the
repair pathways to avoid activation of multiple stress response
mechanisms that could interfere with processing of highly
cytotoxic ICLs and DSBs.
The present results contribute novel candidate factors to be
included in targeted protein profiling analyses by e.g. high-
throughput MRM-mass spectrometry of patient samples to further
evaluate their prognostic value. In addition, the apparent
Melphalan-induced downregulation of specific BER proteins
may provide clues adjuvant therapies to overcome Melphalan
resistance.
Results and Discussion
Melphalan Resistance in RPMI8226 Cells is Accompanied
by Increased S-phase Progression and Reduced G2/M
Arrest Compared to Melphalan Sensitive Parental Cells
To mimic Melphalan concentrations observed in plasma of
patients receiving oral Melphalan treatment [35,36] and to
maintain similar growth rate of the sensitive/resistant cell lines,
the LR5 cells were added Melphalan to a final concentration of
1 mM at each passage. At this drug concentration we observed
essentially identical growth rate (Fig. 1A) and similar cell cycle
distribution (Fig. 1B, 0 hrs) of LR5 compared to the unexposed,
parental 8226 cells (referred to as steady state growth conditions in
the following). This is important when DNA repair proteins are
the subject of analysis, since the expression of many proteins
involved in DNA damage signaling and repair are strictly cell cycle
regulated [37–43]. Whereas addition of Melphalan to a final
concentration of 2.5 mM to both cell lines mediated a weak
reduction of the proliferation of the resistant LR5 cells,
proliferation of the sensitive cells essentially ceased 3 days after
Melphalan addition (Fig. 1A). Flow cytometry analysis indicated
that Melphalan exposure mediated a markedly delayed S-phase
progression in the sensitive- compared to the resistant cells,
followed by accumulation of cells in G2 (Fig. 1B). This delayed S-
phase progression conforms to introduction of DNA lesions that
delay or stall replication forks, as well as to potential accumulation
of unrepaired damage that activates the G2/M checkpoint and
induces apoptosis. This is supported by a markedly increased sub-
G1 fraction among the sensitive cells from 72 to 96 hours post
Melphalan addition, concomitant with a selective loss of cells in
G2 (Fig. 1B, bottom panels). Conversely, S-phase progression was
much less affected in the resistant LR5 cells, in agreement with a
more efficient removal or bypass of replication-blocking DNA
lesions, potentially accompanied with less efficient intra-S and G2/
M checkpoints.
Melphalan Resistance in RPMI8226 Cells is Accompanied
by Modulated Expression of Proteins Belonging to
Several DNA Damage Response Pathways
To investigate the molecular mechanisms underlying Melpha-
lan resistance in the adapted LR5 cell line in more detail, and the
potential role of DNA-repair and signaling proteins, we performed
a quantitative western analysis of a panel of more than 50 proteins
directly and/or indirectly involved in the DNA damage response.
We chose western analysis since many of the involved proteins
exist in the cells at levels that precluded a broad quantitative mass
spectrometry profiling by our current instrumentation unless pre-
enrichment strategies were included. Protein levels were analyzed
both during continuous growth of the sensitive/resistant cells, as
well as subsequent to a 6 h exposure to high-dose Melphalan
(50 mM), corresponding to the lag-period reported where the
conversion of mono-adducts into ICLs reaches a maximum [15].
Expression levels in the Melphalan resistant LR5 cells relative to
the sensitive parental cells under continuous growth are summa-
rized in Fig. 2, and demonstrate marked changes in the steady-
state levels of several proteins belonging to different DNA damage
signaling- and repair pathways. Most notably, we observed
upregulation of the DNA damage sensory kinase ATR in the
resistant cells with a concomitant decrease in ATM, indicating
DNA Repair Switch in Melphalan Resistance
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increased capability to detect and process replication-blocking
lesions in the resistant cells. Moreover, several proteins involved in
DSB repair by NHEJ were found to be upregulated in the resistant
cells, most notably LIG4 and XRCC4. Conversely, three BER
glycosylases (NEIL1, UNG2 and MPG) were found to be
downregulated, indicating a reduced base excision capacity in
the resistant cells. Somewhat surprisingly, we found no apparent
up-regulation of the FA-pathway in the LR5 cells, as determined
from the total level of FANCD2 as well as the apparent absence of
monoubiquitinylated FANCD2 (Fig. 2). Ub-FANCD2 is consid-
ered an essential link between the FA protein complex and the
BRCA1 repair machinery [44], and has previously been reported
to be modestly upregulated in LR5 cells adapted to growth in 5mM
Melphalan [24]. However, in another multiple myeloma cell line,
U266, no increase in FANCD2 was observed subsequent to
growth adaption to 6 mM Melphalan [17].
Among the cell-cycle and growth regulatory proteins we found
that the oncogenes c-MYC and 14-3-3b were upregulated in the
resistant cells, while Cdc25B/C and the tumor suppressor 14-3-3s
are markedly downregulated in the same cells. 14-3-3s is a known
inhibitor of G2/M-progression in many cell types subsequent to
DNA damage [45], while 14-3-3b has been shown to stimulate
proliferation [46]. The markedly shifted expression of these 14-3-3
proteins might thus contribute to the apparently reduced G2/M
checkpoint-activation in the resistant cells.
Melphalan Resistant Cells have Reduced Expression of
Several BER-initiating Glycosylases and Display Cross-
resistance to Agents that Mediate Non-bulky DNA Base
Alterations
BER is the dominating cellular pathway for repair of non-bulky
DNA base damage [47]. A function of BER in the repair of
Melphalan-induced DNA damage is thus not obvious, unless
secondary lesions are induced by yet unidentified mechanisms.
One exception is, however, the finding that the DNA glycosylase
NEIL1 is able to excise a bulky unhooked psoralen-induced ICL
by cleavage of the glycosidic bond between the deoxyribose and
the crosslinked base [48] Surprisingly, however, we observed a
marked downregulation at steady state of 3 out of 6 initiator
glycosylases of BER (Fig. 3 A) in the LR5 cells whereas levels of
downstream (damage- general) enzymes (APE1, POLB, FEN1,
LIG1 and LIG3) remained unaltered (Fig. 2). Interestingly, the
downregulated glycosylases NEIL1 (0.3060.20), UNG2
(0.4560.06) and MPG (0.7360.09), share a common character-
istic in that they are able to excise their respective base substrates
(oxidised pyrimidines, uracil, and alkylated bases, respectively)
from both dsDNA- as well as ssDNA contexts. Conversely, the
levels of TDG, MBD4 and OGG1 that are all strictly dsDNA-
specific, were essentially unaltered in the LR5 cells compared to
the parental 8226 cells. Subsequent to a 6 h treatment with 50 mM
Melphalan, UNG2 was upregulated in both the sensitive and
resistant cells whereas little modulation of the protein levels of the
other glycosylases was observed (Fig. 3A). Since UNG2 is strictly
Figure 1. Melphalan resistance in RPMI8226 cells is accompa-
nied by increased S-phase progression and reduced G2/M
arrest. Cell growth rate (A) and cell cycle distribution (B) of sensitive
(8226) and resistant (LR5) cells exposed or non-exposed to 2.5 mM
Melphalan. (A) Exposure to 2.5 mM Melphalan greatly reduced the
proliferation of the sensitive cells, while a minor effect upon the
proliferation of resistant cells was observed. (B) Flow cytometric analysis
of cell cycle phases shows that 2.5 mM Melphalan caused delayed S-
phase progression in sensitive cells followed by G2/M arrest.
Conversely, progression throughout S-phase was less affected in the
resistant cells exposed to Melphalan. Moreover, the resistant cells were
able to overcome the G2/M arrest induced by Melphalan and re-enter
the cell cycle. Per cent cells in each of the cell cycle phases are indicated
above the histograms. The fraction of cells in subG1 is indicated, but
not illustrated in the gated histograms.
doi:10.1371/journal.pone.0055493.g001
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cell-cycle regulated with the highest expression in late G1/S-phase
[40,49], the most likely explanation for the apparent upregulation
is likely accumulation in S-phase of cells at the high (50 mM)
concentration of Melphalan used in the experiment. This was also
supported by the more pronounced upregulation in the sensitive
cells which conforms to the strong S-phase accumulation
subsequent to Melphalan treatment (Fig. 1B). The reduced level
of UNG2 protein was also accompanied by a reduced uracil-
excision activity in resistant cell free extracts and in both cell
extracts this activity increased subsequent to acute exposure to
50 mM melphalan (Fig. 3B). Moreover, the increased activity was
significant (P,0.05) in the sensitive cells only, in agreement with
the UNG2 western analysis. Repeating the excision experiments in
presence of the UNG-specific inhibitor Ugi encoded by the
bacteriophage PBS2 [50] demonstrated that the overall contribu-
tion from other glycosylases than UNG to the total uracil-excision
activity was ,10% in both cell lines (Fig. 3B). Thus the reduced
uracil-excision capacity in the resistant cells was mediated
primarily by reduced level of UNG protein.
To monitor whether the markedly reduced level of NEIL1 as
well as the low level of OGG1 (barely above detection level,
Fig. 3A) was reflected in the genomic content of genomic oxidative
damage, we analyzed the genomic 8-oxodG in both cell lines at
steady state as well as 6 h subsequent to acute 50 mM Melphalan
exposure. As illustrated in Fig. 3C, the steady state 8-oxodG level
in the resistant cells was about twofold higher than that of the
sensitive cells. Remarkably, however, acute exposure to 50 mM did
not mediate any increase in 8-oxodG in any of the cell lines. To
investigate the underlying cause of genomic 8-oxodG accumula-
tion in the resistant cell line in more detail, we also monitored the
Figure 2. Steady state expression levels of proteins involved in DNA repair and DNA damage signaling response in 8226-LR5 cells
relative to parental cells. Protein levels were assessed by quantitative western blot analysis using specific antibodies against target proteins. Each
bar represent the mean expression ratio of the target protein in the LR5 (resistant) cells relative to the reference value of 1 (dotted line) in the
sensitive cells subsequent to normalization against either b-actin or tubulin (to avoid overlapping signals). Quantitative analysis enclosed an average
of 3 to 5 biological replicates with standard deviations as indicated. The P values were calculated by one sample two tailed t test against a
hypothetical expression ratio set to 1 (no change in expression)..90%,.95% and.98% confidence levels indicated by *, **, and ***, respectively.#
Only non-ubiquitinylated FANCD2 was detected in the analyses.
doi:10.1371/journal.pone.0055493.g002
DNA Repair Switch in Melphalan Resistance
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e55493
total level of reactive oxygen species (ROS) in the two cell lines.
We observed about 20% lower ROS level in the resistant-
compared to the sensitive cells, but no significant difference in any
of the cell lines after treatment with 50 mM Melphalen. In
contrast, treatment with 50 mM of the positive control tert-butyl
hydroperoxide (TBHP) mediated about threefold increased ROS
in both cell lines (Fig. S1). The most likely interpretation of these
results is that the markedly increased accumulation of genomic 8-
oxodG in the resistant cells is not primarily caused by Melphala-
induced ROS, but more likely result from lack of removal of 8-
oxodG formed by endogenous sources of ROS. This would
conform to the apparently very low level of OGG1 in both cell
lines as well as the markedly (threefold) downregulated level of
NEIL1 in the resistant cells.
Next we investigated whether the reduced levels of DNA
glycosylases were accompanied by increased sensitivity towards
agents inducing BER substrate lesions. To this end we subjected
the cells to treatment with the alkylator methyl methanesulfonate
(MMS), H2O2 and the antimetabolite 5-fluorouracil (5-FU). The
latter induces both genomic uracil and 5-FU, both of which are
substrates for UNG2 (reviewed in [51]). In addition, we monitored
potential cross-resistance towards the ICL-inducing agent mito-
mycin C (MMC) and UVB-irradiation (Fig. 4). Notably, the
Melphalan-resistant cells displayed a markedly increased resistance
to both MMS and H2O2 (Fig. 3A,B). This was rather surprising,
given the observed reduced levels of the respective glycosylases
(MPG and NEIL1) that excise the major base lesions induced by
these agents [52–53]. A similar cross-resistance was observed with
low concentrations (1 mM) of 5-FU, whereas at high concentra-
tions (10 mM) the Melphalan-sensitive cells displayed higher
resistance to 5-FU (Fig. 4 B,C). Finally, the Melphalan-resistant
cells displayed cross-resistance to the ICL-inducing agent MMC
(Fig. 4E) whereas both cell lines were equally sensitive to UVB
(Fig. 3F). The latter suggests that modulation of the expression of
NER-factors does not likely contribute to the Melphalan-resistant
phenotype in the 8226 cells.
The apparently increased tolerance of the Melphalan-resistant
cell line towards agents causing structurally minor DNA-base-
lesions (BER substrates) was intriguing. Previous studies have,
however, demonstrated that overexpression of MPG mediates
increased sensitivity towards MMS [54], likely because the
number of AP-sites generated exceeds the capacity of downstream
BER-factors and results in increased levels of cytotoxic repair
intermediates. Furthermore, it was recently demonstrated that
UNG-deficient cells displayed a Cisplatin-resistant phenotype
accompanied by enhanced repair of ICLs and ICL-induced DSBs
[34]. The authors demonstrated that (extrahelical) cytosines
flanking the Cisplatin-ICL underwent preferential oxidative
Figure 3. DNA glycosylases with dual ss/dsDNA substrate
specificity are downregulated in Melphalan-resistant cells.
Levels of DNA glycosylases (A), relative UDG activities (B) and genomic
8-oxodG-content in sensitive and resistant cells prior and after exposure
to 50 mM Melphalan. Western blot analysis revealed downregulation of
UNG2, MPG and NEIL1 (dual ss/dsDNA-specific glycosylases) in the
Melphalan-resistant cells compared to sensitive cells while this was not
observed for the dsDNA-specific glycosylases TDG, MBD4 and OGG1,
the latter barely above the detection level in the cells (A). In agreement
with UNG2 protein levels, activity assays showed that uracil excision
activity was significantly higher in sensitive cells against [3H]dUMP-
containing ss- and dsDNA substrates. Moreover, high dose Melphalan
mediated an apparent increase in UDG activity in both cell lines,
although this was only significant (P,0.05) for the resistant cells.
Addition of the UNG-specific inhibitor Ugi to the reactions demon-
strated that the observed reduced uracil-excision activity in the resistant
cell line was mainly accounted for by reduction of UNG-activity. Each
bar constitutes an average from four independent experiments, each
run in triplicate, with standard deviations as demonstrated. P-values
were calculated using unpaired Student t-test (B). A twofold increased
steady state level of genomic 8-oxodG was found in the resistant
compared to the sensitive cells. Each bar constitutes and average from
three independent experiments with standard deviations as indicated
(C).
doi:10.1371/journal.pone.0055493.g003
DNA Repair Switch in Melphalan Resistance
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55493
deamination in vitro and proposed that UNG-mediated removal of
such flanking uracils induce AP-sites and BER intermediates than
compete with productive ICL DNA repair. Whether such
preferential deamination of cytosine also occurs at Melphalan-
ICLs remains, however, to be established. Nevertheless, since
UNG2, NEIL1 and MPG are major BER initiators of endogenous
Figure 4. Melphalan resistance is accompanied by increased resistance to agents inducing non-bulky BER substrates. Cell were
exposed to MMS (A), H2O2 (B), low (C) and high (D) doses of 5-FU, MMC (E) and UVB (F) assessed by the MTT assay. Viability curves showed that the
Melphalan-resistant cells are cross-resistant to MMS, H2O2, low dose 5-FU and MMC. Conversely, high dose of 5-FU affects the proliferation of resistant
cells in higher extent compared to sensitive cells. Exposure to UVB similarly affected growth of both cell lines. Increasing absorbance correlates
directly with the number of living cells. Standard deviation bars are indicated.
doi:10.1371/journal.pone.0055493.g004
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DNA base damage, decreased steady-state levels of BER repair
intermediates (AP-sites and single-strand breaks (SSBs)) could
mediate a survival benefit during the more complex processing of
Melphalan-induced DNA damage.
Melphalan-Resistance is Accompanied by Reduced Level
of Genomic Alkali-labile Sites (ALS) and Increased
Sensitivity to PARP-1 Inhibition
To investigate whether the reduced levels of BER glycosylases
was also accompanied modulated levels of ALS, including AP-sites
and SSBs, we performed an alkaline comet assay of both cell lines
in the absence of- and subsequent to high dose (50 mM and
100 mM) Melphalan. Notably the resistant cells displayed signif-
icantly lower values of tail DNA both in the absence- and presence
of high dose Melphalan (Fig. 5A) in agreement with the decreased
level of initiator BER glycosylases. However, ALS are also formed
by glycosylase-independent routes. AP-sites are formed by
spontaneous base loss and are further processed to SSBs by AP-
endonucleases. In addition SSBs are formed by oxidative attack at
the sugar-phosphate backbone or as intermediates in other DNA-
processing pathways, including repair of ICLs. An alternative or
additional explanation to the reduced levels of ALS in the resistant
cells could thus be increased processing of AP sites and SSBs.
Notably, we did not detect any overt changes in expression of
proteins involved in damage-general steps of BER/SSBR,
including APE1, POLB, PCNA, LIG1, and LIG3 (Fig. 2). One
exception was a modestly increased level of the scaffolding protein
XRCC1. However, whereas the total level of the nick-sensing
enzyme Poly(ADP-ribose) polymerase 1 (PARP-1) was similar in
the two cell lines, a high molecular weight (HMW) form
apparently constituting autoribosylated and activated PARP-1
[55] was observed exclusively in the resistant cells, even after
treatment with 50 mM Melphalan (Fig. 5B, upper and middle
panels). To further substantiate the activation of PARP-1 by
autoribosylation, we treated the cells with 4-amino-1,8-naphtha-
limide (4-AN), a potent inhibitor of PARP-1 and of SSB repair
[56]. This mediated a complete loss of the HMW (PARylated)
form and a concomitant increase in the faster migrating
unmodified PARP-1 (Fig. 5C), in agreement with loss of
autoribosylation. The markedly increased PARP-1 activation
was somewhat surprising given the lower level of PARP-1
trigger-lesions (ALS) in the resistant cells and suggests that the
majority of these sites are efficiently repaired in the resistant cells.
Notably, the increased enzymatic activity of PARP-1 in the
resistant cells conforms to the upregulated level of c-MYC (Fig. 2).
c-MYC was recently demonstrated to regulate the activity of
PARP-1 via downregulation of the PARP-1 inhibitor protein
BIN1, thereby increasing Cisplatin resistance [57].
To test whether increased PARP-1 activation also mediated
altered sensitivity to PARP-1 inhibition, we next treated both cell
lines with 4-AN and subjected the cells to MTT assay. As
illustrated in Fig. 5D (upper panel), the Melphalan-resistant cells
were significantly more sensitive to PARP-1 inhibition than the
parental cell line. The increased sensitivity of Melphalan-resistant
cells to PARP-1 inhibition was also observed when using another
PARP-1 inhibitor, KU58684 (Fig. 5D, lower panel).
In summary, this suggests that the Melphalan-resistant cells
have a lower level of ALS that may impede productive processing
of Melphalan-ICLs. The lower level of ALS is apparently
mediated both by reduced formation of AP-sites by glycosylases
and by improved PARP-1- induced processing of ALS as
substantiated by the unique sensitivity of the resistant cells to
blockage of SSB repair. However, PARP-1 is also involved in
other cellular defense mechanisms such as repair of DSBs and an
effect of PARP-1 inhibition via such alternative routes could thus
not be excluded.
Proteins Involved in NHEJ are Up-regulated in Melphalan
Resistant Cells
DNA DSBs are repaired via two major pathways; homologous
recombination repair (HRR), and non-homologous end-joining
(NHEJ) [58]. HRR takes advantage of homologous DNA
templates present in late S and G2 and is thus error-free. NHEJ
simply re-joins broken DNA ends, but is error-prone since it often
involves processing of the ends to produce ligatable ends. NHEJ
may thus result in chromosomal translocations, which are
commonly observed in multiple myeloma. NHEJ may operate
throughout the entire cell-cycle and appears to be the major route
for DSBs repair in vertebrates. The classical NHEJ pathway is
initiated by binding of the KU heterodimer to the ends of a DSB,
and subsequent recruitment of the catalytic subunit of DNA-PK
(DNA-PKcs) to form the active holoenzyme. DNA-PKCS is
autophosphorylated and also phosphorylates other NHEJ proteins
such as RPA2, WRN, XLF, LIG4, XRCC4 and Artemis to
facilitate end-joining and repair ([59] and references therein).
More recently alternative NHEJ pathways have been described,
termed Alt-NHEJ, which is dominated by microhomology-
mediated end-joining [58]. Alt-NHEJ is mediated by PARP-1/2,
and involves WRN and ligation by LIG3/XRCC1. Interestingly,
the protein quantitation experiments indicate that several factors
of the classical NHEJ pathway are upregulated in the Melphalan-
resistant cells (Fig. 2 and 6A), with LIG4 (2.5160.08, p = 0.001),
XRCC4 (1.6960.19, p = 0.02), and RPA2 (1.6960.0.34, p = 0.03)
showing significant upregulation. Artemis, which is involved in
DNA end-processing prior to ligation, is present in two forms in
both parental and resistant cells. Notably, however, a marked shift
from the low-MW form conforming to unphosphorylated Artemis,
to the high-MW form conforming to phosphorylated (activated)
Artemis was observed in the resistant cells (Fig. 6A). These results
indicate that the final steps of NHEJ encompassing end-processing
and ligation are upregulated in the Melphalan-resistant cells.
No marked alteration in the steady-state level of most proteins
involved in HRR (RAD50, RAD51, RAD52, MRE11) was
observed in the Melphalan-resistant cells (Fig. 2). One exception
was, however, a moderate increase in BRCA1 (1.4360.10).
However, subsequent to high dose Melphalan, the level of BRCA1
was reduced in both the sensitive (0.5460.32) and resistant
(0.5660.11) cells, suggesting a down-regulation of HRR during
high-dose treatment (Fig. 6B). In summary, these results indicate
that upregulation of NHEJ, including a potential involvement of
PARP-1 to facilitate synapsis of DSBs [60], may contribute to the
Melphalan-resistant phenotype.
ATM and ATR Signaling Pathways are Modulated in
Melphalan Resistant Cells
The apparent switch in the levels of NHEJ versus HRR
prompted us to investigate the involvement the damage-signaling
kinases involved in DSB repair. DSB repair is initiated by three
kinases belonging to the family of phosphatidylinositol 3-kinase-
related kinases (PIKKs); DNA-PK, ATM (ataxia telangiectasia
mutated) and ATR (ataxia telangiectasia mutated) [61]. While
DNA-PK and ATM primarily respond to DSBs induced by e.g.
ionizing radiation, ATR responds to replication blocks or other
factors that induce extended stretches of ssDNA. Recent research
has, however, demonstrated that the ATM- and ATR-initiated
pathways are not separated, but highly interconnected and that
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ATM and ATR in fact may directly interact and activate each
other [62].
Whereas no difference in the level of DNA-PKcs was observed
in the resistant and sensitive cells (Fig. 6A), marked alterations
were observed for ATM and ATR. As illustrated in Fig. 6B, the
steady state-levels of ATM were significantly higher in the
Melphalan-sensitive cells, whereas this was reversed for ATR.
Moreover, subsequent to high-dose Melphalan, substantially more
activated ATM (pS1981) was observed in the sensitive cells,
whereas the level of activated ATR (pS428) was highest in the
resistant cells. The increased CHK2-activation in the resistant cell
line was also intriguing, since CHK2 is generally regarded as a
tumor suppressor mediating cell cycle delay/arrest, apoptosis and
DNA repair and is a canonical target of ATM [63]. Likely, an
effect of CHK2 is not mediated via phosphorylation of p53, since
p53 is mutated in RPMI8226 cells [64], as is also substantiated by
the reduced level of p21 in the resistant cells (Fig. 2). Furthermore,
this would have resulted in increased cell-cycle arrest and
apoptosis in the resistant cells, which is not substantiated by the
cell cycle analyses (Fig. 1B), the lack of modulation of pro- (BAX)
and anti- (BCL2) apoptotic proteins (Fig. 2) and the low degree of
PARP-1 cleavage (Fig. 3B).
To gain further insight in the relative roles of PI3-kinase-like
kinases (PIKKs) as well as the downstream kinases CHK1/2 in
mediating Melphalan resistance, we treated the resistant cells with
varying concentrations of inhibitors against ATR (VE821), ATM
(KU55933), DNA-PK (NU7441) and CHK1/2 (AZD7762) in the
presence- or absence of Melphalan. Whereas a modestly decreased
proliferation was observed with each of the inhibitors in the
absence of Melphalan, a marked inhibition was observed when
either CHK1/2, DNA-PK or ATR was inhibited in the presence
of Melphalan. Notably, inhibition of ATR caused the strongest
inhibition of proliferation, whereas inhibition of ATM mediated
no significant reduction in proliferation. This corroborates the
marked shift in expression and activation of ATM and ATR in the
resistant cells and strongly supports that ATR plays a significant
role in mediating Melphalan resistance in our experimental
system. Moreover, it is tempting to speculate that ATR may
Figure 5. Assessment of alkali-labile sites in Melphalan sensitive and resistant cells. (A) Comet assays demonstrated that the resistant LR
cells contained a significantly lower number of alkali-labile sites than the sensitive cells both at steady-state and subsequent to high-dose melphalan
treatment. Per cent tail DNA of the comets is presented in dot plots with average and corresponding SEM. P values were calculated using an unpaired
two-tailed t-test. R: resistant, S: sensitive. 100 comets were randomly selected and evaluated from one experiment at each treatment. (B) Western blot
analysis showed that PARP-1 is activated via poly-ADP(ribosyl)ation only in the resistant cells suggesting that SSB repair and potentially also DSB
synapsis is enhanced in the resistant cells. (C) Activation of PARP1 by PARylation in the resistant LR5 cells was completely abolished subsequent to
treatment with the PARP-1 inhibitor 4-AN. (D) Inhibition of PARP-1 by 4-AN or KU58684 obstructs the proliferation of resistant cells while having a
minor effect on the sensitive cells.
doi:10.1371/journal.pone.0055493.g005
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contribute to NHEJ activation via activation of DNA-PK. A
function of DNA-PK downstream of ATR would also conform to
the lower effect of DNA-PK- compared to ATR inhibition on
Melphalan sensitivity (Fig. 7). Notably ATR-dependent activation
of DNA-PK has previously been observed subsequent to UV-
induced replication stress in HeLa cells and this activation was
mediated by phosphorylations on DNA-PK distinct from those
observed subsequent to ionizing radiation [65]. Moreover, DNA-
PK has been shown to phosphorylate CHK2 [66]. Although we
did not observe Melphalan-induced phosphorylation of DNA-PK
by using a phospho-specific pT2609 antibody (data not shown),
potential activation of DNA-PK and NHEJ via ATR as well as the
individual roles of CHK1/2 in mediating Melphalan resistance
clearly warrants further investigation.
Phosphorylated cH2AX foci are Formed more Rapidly
and Persist for a Shorter Time in Melphalan Resistant
8226 Cells
The level of nuclear foci of cH2AX is generally used to monitor
the number of DSBs that are marked for processing subsequent to
genotoxic stress and is also a sensitive marker of DNA damage
induced by ICL-inducing agents [67]. To monitor a potential
differential formation of- and persistence of such foci in the two
cell lines, cells were fixed at different time points subsequent to
treatment with 25 mM Melphalan, incubated with cH2AX
antibodies, and nuclear cH2AX quantified subsequent to confocal
analysis. Due to the half-life of Melphalan in cell culture medium
at 37 degrees (, 1 h), cell washing after pulse drug exposure was
not performed [68,69]. Notably, a significantly higher number of
Figure 6. Level of DNA repair proteins (A) and damage
signaling kinases (B) involved in DSB repair in Melphalan-
sensitive and -resistant cells. (A) Quantitative western blot analysis
revealed that the NHEJ proteins DNA ligase IV, XRCC4 and RPA2 are
significantly and constitutively upregulated in Melphalan-resistant cells.
In addition, KU80 and phosphorylated Artemis was consistently,
although not significantly upregulated. Exposure to high dose
Melphalan did not mediate further alteration of NHEJ proteins in the
cell lines. (B) The steady-state levels of the kinase ATR and its
phosphorylated form are increased in Melphalan resistant cells.
Conversely, ATM is constitutively downregulated in the same cells.
Rather than activation of CHK1, increased steady-state phosphorylation
of pCHK2 was observed in resistant cells. Notably, high dose Melphalan
strongly activates CHK2 in both sensitive and resistant cells but was
consistently higher in resistant cells. Moreover, BRCA1, which is slightly
induced in resistant cells, becomes markedly reduced in both sensitive
and resistant cells after high dose Melphalan indicating temporary
downregulation of HRR. Also note the the lack of apparent
monoubiquitinylation of FANCD2 (B). b-actin was used as reference
for quantitative analysis.
doi:10.1371/journal.pone.0055493.g006
Figure 7. Effect of PI3-kinase-like kinase (PIKK)- and CHK1/2
inhibitors on the proliferation of 8226-LR5 cells. The MTT assay
was used to monitor the survival after 72h incubation with the various
inhibitors 62.5 Melphalan. CHK1/2 inhibitor AZD7762 (0.1 mM), DNA-PK
inhibitor NU7441 (0.2 mM), ATM inhibitor KU55933 (3 mM), ATR inhibitor
VE821 (1 mM). Whereas a moderate inhibition on proliferation was
observed with either inhibitor alone, strong inhibition was observed in
combination with melphalan for the CHK1/2, DNA-PK and ATR
inhibitors. Each bar represents the mean of at least 5 independent
experiments with standard deviations as indicated. P-values were
calculated using 2-sample t-test with equal variance. .95%, .99% and
.99.9% confidence levels indicated by *, **, and ***, respectively.
doi:10.1371/journal.pone.0055493.g007
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foci were observed in the non-treated, resistant cells (0 hours).
Subsequent to Melphalan treatment, a markedly increased
accumulation of cH2AX foci was observed at early time points
in the resistant- compared to the sensitive cell line (Fig. 8 A,B). In
the Melphalan-resistant cells the number of foci decreased at 24 h,
whereas an increase in the number of foci was observed in the
sensitive cells. These results are entirely in agreement with the
proposed increased repair of Melphalan-induced DNA damage in
the resistant cells.
Concluding Remarks
The present study reveals several DNA damage response factors
as novel potential contributors to Melphalan resistance. Our
results are in agreement with recent findings that productive repair
of Cisplatin-ICLs is suppressed by base excision repair interme-
diates in the vicinity of the Cisplatin-ICL [34]. Here we
demonstrate that three DNA glycosylases, UNG2, NEIL1 and
MPG are significantly downregulated in the Melphalan-resistant
cells. This is further corroborated by a markedly reduced UNG
enzyme activity as well as doubling of the genomic 8-oxodG
content in the resistant cells. Moreover, the lowered expression of
the glycosylases was accompanied by an increased tolerance
towards agents inducing their respective DNA base substrates.
This is in agreement with previous findings demonstrating that
overexpression of MPG increases sensitivity towards temozolo-
mide [70] as well as MMS [71]. The genomic accumulation of 8-
oxodG was apparently not caused by an increased level of ROS in
the resistant cells and did not change subsequent to high-dose
Melphalan. Thus a more likely explanation is that the observed
accumulation of 8-oxodG is mediated by reduced excision by
DNA glycosylases. Notably, OGG1 is regarded the prime
glycosylase for removal of genomic 8-oxoG, with NEIL1 as a
ubiquitously expressed [72]. Since the OGG1 expression was
barely above the detection level in both cell lines, the markedly
increased 8-oxodG level is most likely mediated by the threefold
reduced level of NEIL1 in the resistant cells. It is currently not
clear whether the marked downregulation of UNG2 mediates a
corresponding increase in overall genomic uracil. Furthermore, it
remains to be elucidated whether preferential deamination of
cytosine occurs in regions flanking Melphalan-ICLs similar to
what is observed at Cisplatin-ICLs. To our knowledge, the three-
dimensional structure of a DNA Melphalan-ICL has not been
resolved. Whether this ICL mediates the same degree of single-
stranded DNA and extrahelical bases flanking the lesion as seen in
the cisplatin-ICL [73], thus remain to be investigated. This could
certainly also impact the rate of oxidative base damage at
Melphalan ICLs. In conclusion, downregulation of initiator BER
glycosylases may provide a selective advantage by lowering the
levels of ALS repair intermediates that would obstruct ICL
processing. Reduced excision of base lesions such as uracil and 8-
oxoG, which both per se are regarded non-cytotoxic, would also
make biological sense from another point of view, by increasing
the overall mutation frequency in the resistant cells. This would
likely be beneficial under the selective pressure imposed by
Melphalan therapy.
A second factor contributing to reduced steady state levels of
ALS would be increased repair of such sites. Although we did not
observe a general upregulation of factors involved in AP-site or
SSB processing, the observation of PARP1 autoribosylation
exclusively in the resistant cells strongly support that such factors
are more efficiently recruited to ALS in the resistant cells. This was
also corroborated by the increased sensitivity to PARP-1 inhibition
of the resistant cell line. Whether this increased sensitivity is
mediated exclusively via reduced SSB-repair in the cells, however,
Figure 8. Melphalan-resistant cells have a more rapid kinetics
of cH2AX foci formation than sensitive cells. (A) The number of c-
H2AX foci per cell nucleus (N.13) was manually quantified for each
time point and the experiment was performed in triplicate. Corre-
sponding standard deviation bars are indicated. P,0.01 at all time
points as calculated using 2-sample t-test with equal variance. (B)
Representative confocal images of the cells at different time points
subsequent to Melphalan treatment. Foci formation was monitored
using cH2AX polyclonal antibody (red) and due to the significant
fraction of NFkB protein present in the cytoplasm of these cells, NFkB
p65 mouse monoclonal antibody was used as control for cytoplasmic
staining (green).
doi:10.1371/journal.pone.0055493.g008
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remains elusive, since PARP-1 is also involved in other processes
including DSB repair by mediating synapsis of strand breaks in
NHEJ [60]. A recent study also demonstrated that PARP-1 bound
with higher affinity to Cisplatin-induced ICLs than to undamaged
DNA [74], supporting that PARP-1 may be involved in the
recruitment of factors contributing to ICL- or ICL-induced DSB
processing. If this is so, co-treatment with PARP-1 inhibitors
should certainly be investigated further as a means to overcome
sensitivity to ICL-inducing agents by inducing symbiotic lethality.
Our data suggest the potential involvement of an ATR/DNA-
PK/CHK2 pathway in the stress response triggered by Melphalan
and underscores that the classical ATM-CHK2/ATR-CHK1
pathways are likely much more versatile and dynamic than
previously anticipated. This is also substantiated by studies of
cisplatin-induced cytotoxicity in renal cells, in which ATR, but not
ATM and DNA-PK is specifically activated during Cisplatin
treatment, and that this results in ATR-dependent phosphoryla-
tion of both CHK1 and CHK2 [75]. In the same study CHK1 was
degraded via the proteosomal pathway following phosphorylation,
whereas CHK2 remained activated. The authors also report that
Cisplatin-induced p53 activation and apoptosis are suppressed in
ATR-deficient fibroblasts. The lack of apparent apoptosis-induc-
tion in the RPMI8226 cells may be explained by the mutant p53
protein, and the ATR-CHK2 activation rather mediates increased
efficiency in the repair of DSBs and/or modulated checkpoint
signaling. Moreover our data also support that DNA-PK may be
involved in CHK2 activation, in accordance with previous
observations [66]. DNA-PK may thus have a dual function in
the cells in mediating CHK2 activation (together with ATR) and
in initiating NHEJ. Upregulation of several proteins involved in
the classical NHEJ pathway could then contribute to the observed
increased efficiency in the repair DSBs, potentially involving
increased DSB synapsis by autoribosylated PARP-1 [60].
In summary, we have identified several novel candidate DNA
damage response proteins that may contribute to development of
Melphalan resistance. We will now include these candidate
proteins in SID-MRM-based targeted quantitative proteomics
analyses in a larger patient cohort to determine their value in
overcoming drug resistance in multiple myeloma, either as targets
for substitution therapies or adjuvants for existing therapies.
Materials and Methods
Cell Lines
Multiple myeloma cell lines 8226 and its Melphalan resistant
derivative 8226-LR5 [15], were kindly provided by Prof. William
S. Dalton at the H. Lee Moffitt Cancer Center & Research
Institute at the University of South Florida. Cells were cultured in
RPMI 1640 (Sigma Aldrich) medium containing 10% (v/v) FBS
(GIBCO) heated for 30 minutes at 56uC, 1% (v/v) of 200 mM L-
glutamine (Lonza), 1% (v/v) of 10 mg/mL gentamicin (GIBCO)
and 1% (v/v) of 250 UG/mL Amphotericin B (GIBCO).
Melphalan resistant 8226-LR5 cells were maintained under
constant selection through the addition of 1 mM Melphalan
(Sigma-Aldrich, St. Louis, MO) twice per week. Subsequent to
addition of the maintenance Melphalan, 8226-LR5 cells were
allowed to grow at least for 3 days prior to any additional
treatment or cell extract preparation.
Cell Treatment with Melphalan and Preparation of Cell
Extracts
Cells were treated with 50 mM Melphalan or vehicle control
(acidified ethanol) for 6 hours in a ratio 1.106/mL, harvested and
washed 3 times with PBS. Cells were resuspended in buffer 1
containing 10 mM Tris-HCl pH 8.0, 200 mM KCl and diluted in
the same volume (cells+buffer 1) of buffer 2 (10 mM Tris-HCl
pH 8.0, 200 mM KCl, 2 mM EDTA, 40% glycerol, 0.5% NP40,
1 mM DTT, 1% phosphatase inhibitor cocktails 1 and 3 (Sigma),
and 2% Complete EDTA-free (Roche)). After incubation for 1.5 h
at 4uC, cell extracts were sonicated for 2 min, following
centrifugation at 14,000 rpm for 10 min. Supernatants were
collected and used for western blot analysis. Protein concentration
was determined by using the BioRad protein assay (BioRad
laboratories).
Western Blot Analysis
Proteins were heated in LDS loading buffer (Invitrogen) prior to
separation on pre-cast 4–12% denaturing NuPAGE gels using
MOPS run buffer (Invitrogen) and electroblotting to PVDF
membranes (Immobilon, Millipore) for 1:30 h at 30 V. Western
analysis was performed using the antibodies targeted against the
following (dilutions or concentrations of antibodies are indicated):
Artemis (ab35649, 1:500), ATR (ab10312, 1:15000), Chk1
(ab2845, 1:3000 dilution), Cdc5L (ab51320, 1:100), p21
(ab18209, 0.5 mg/mL), c-H2AX (ab2893, 1:1000), 14-3-3b
(ab16859, 1:2000), PRP19 (ab27692, 1 mg/mL), DNA polymerase
b (ab3181, 1:200), PCNA (ab29, 0.5 mg/mL), KU80 (ab3107,
0.5 mg/mL), MSH2 (ab16833-50, 1 mg/mL) DNA ligase 1 (ab615,
1:3000), DNA ligase 3 (ab587, 2 mg/mL) and XPA (ab65963,
1 mg/mL), MPG (ab55461, 1 mg/mL) from Abcam; pATM
(4526S, 1:1000), pATR (2853, 1:1000), pChk2 (2661, 1:1000),
pS317Chk1 (2344, 1:1000), pS345Chk1 (2348, 1:1000), Cdc25B
(9525, 1:1000), Cdc25C (4688, 1:1000), pCdk1 (9111, 1:1000) and
BAX (2772, 1:1000) from Cell Signaling; Cdk2 (sc-748, 1:1000), c-
Myc (sc-42, 1:500), Bcl-2 (sc-65392, 1:1000), MLH1 (sc-56159,
1:1000), XRCC1 (sc-11429, 1:500), ERCC1 (sc-10785, 1:1000),
FANCD2 (sc-20022, 1:1000), DNA-PK (sc-9051, 1:1000), MBD4
(sc-10753, 1:1000), MRE11 (sc-5859, 1:500), Rad50 (sc-20155,
1:1000), Rad51 (sc-8349, 1:1000), Rad52 (sc-8350, 1:1000), RPA2
(sc-53496, 1:1000) from Santa Cruz; ATM (A300-299A, 1:5000),
BRCA1 (A300-000A, 1:5000), FEN1 (A300-256A, 1:10000) from
Bethyl laboratories; p53 (MS-105-p1, 0.5 mg/mL) from Neo
markers; PARP-1 (04–575, 1:1000) from Millipore; poly(ADP-
ribose) from Trevigen (4335, 1:1000) DNA ligase 4 (HPA001334,
1:1000) from Sigma; XRCC4 (GTX109632, 1:1000) from Gene
Tex; CDC4 (39–5800, 0.5 mg/mL) from Zymed; 14-3-3s
(H00002810, 1:1000), TDG (H00006996, 1:1000) and CDK1
(HPA003387, 1:1000) from Abnova; WEE1 (AP8106b, 0.5 mg/
mL) from Abgent. The polyclonal antibodies PAPE1 and PU059
recognizing APE1 and the catalytic domain of UNG, respectively,
were generated in our own lab (0.5 mg/mL dilution). The NEIL-1
and OGG1 polyclonal antibodies were kindly provided by Prof.
Magnar Bjøra˚s at the University of Oslo. Anti-b-actin mouse
monoclonal antibody (ab8226, Abcam, 1:10000) was used to
normalize the data. After incubation with HRP-conjugated
secondary antibodies (Dako Denmark, 1:5000), membranes were
incubated with SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Scientific) and bands were detected on a digital
imaging system IS4000R Kodak (Fisher Scientific). One exception
was parallel detection of PARP-1/PARylated PARP-1, which was
performed on the Odyssey platform (Li-Cor Biosciences – GmbH)
subsequent to incubation with Goat anti-mouse IRDye800LT and
goat anti-rabbit IRDye680LT secondary antibodies (Li-Cor
Biosciences). Quantitative analysis was performed using 3 to 5
biological replicates, each consisting of a set of sensitive and
resistant cells both at normal growth and subsequent to treatment
with high dose Melphalan for 6 hours. Band densities of target
proteins were measured for each replicate by using the Kodak
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Molecular Imaging software version 4.0.1. After subtracting
background intensity values, densities of target proteins of each
replicate were normalized according to -b-actin or -b-tubulin
densities. After normalization, ratios of band densities of target
proteins in resistant untreated cell extract versus sensitive
untreated cell extract were calculated. The mean of 3 to 5
measurements of ratios Rc/Sc was calculated and the correspon-
dent standard deviations were obtained using the following
formula:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
(x{x)2
(n{1)
r
, where x is the sample mean average and n
is the sample size, described as STEDVA function in Excel.
Flow Cytometry
For FACS analysis, one million cells were fixed in ice-cold
100% methanol and stored at 4uC until DNA measurement. The
cells were washed with cold phosphate-buffered saline (PBS) and
incubated with 200 ml of DNase-free RNAse A in PBS (100 mg/
ml) for 30 min at 37uC before DNA staining with 200 ml of
propidium iodide (50 mg/ml) at 37uC for 30 min. Cell cycle
analyses were performed by using a BD FACSAria cell sorter (BD
Biosciences). Propidium iodide stained cells were analysed at
488nm excitation (blue laser) and 575 nm emission. Cell cycle
fractions were determined by using the BD FACSDiva software
(BD Biosciences).
Viability Assays
The 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium
bromide (MTT) assay was performed using Melphalan, methyl
methanesulfonate (MMS), H2O2, 5-Fluorouracil, Mitomycin C
(MMC) and 4-Amino-1,8-naphthalimide (4-AN), ATM inhibitor
(KU55933) from Santa Cruz ATR inhibitor (VE821) from Axon
Medchem, and DNA-PK inhibitor (NU7441) and CHK1/2
inhibitor (AZD7762) from Selleckchem. The PARP1-inhibitor
KU58684 (Kudos/AstraZeneca) was kindly provided by Dr.
Franc¸oise Dantzer at the University of Strasbourg. Exposure to
UVB (312 nm) was performed using ultraviolet lamp from Vilber
Lourmat. Briefly, myeloma cells resuspended in RPMI 1640
medium were added to 96-well plates (16104 cells/100 ml/well),
and then exposed to varying concentrations of agents (100 ml/well).
Drugs used in the cytotoxicity assays were used at concentrations in
the same range as previously reported IC50 values in RPMI8226 for
5-FU [76] and H2O2 [77], and in lymphocytes for MMS and MMC
[78]. Cells exposed to ultraviolet radiation were resuspended in PBS
instead of RPMI medium prior to addition in 96-well plates (26104
cells/50 ml/well). After irradiation with 100 J/m2 UVB, 150 ml of
RPMI medium were added to each well to allow cell proliferation.
Wells containing only medium and medium with a particular agent
were also included as controls. Results were measured at 0, 48, 72
and 96 hours after treatment. After each time point, 100 ml were
removed from each well and 100 ml of 1 mg/ml MTT were added
to each well, followed by incubation at 37uC in culture hood for 4
hours. Subsequently, 130 ml were carefully removed from each well
and acidified isopropanol (100 ml) was added to the plates. Plates
were covered with tin foil and agitated in orbital shaker for 1 hour
prior to absorbance measurement in a Fluostar optima plate reader
(BMG labtech). Measurements were performed at 590 nm with a
reference filter of 620 nm. Standard deviations for each time point
are indicated.
UDG Assay
Uracil DNA glycosylase activity was measured against
[3H]dUMP-containing calf thymus DNA (U:A) as described
(Kavli et al, 2002). Briefly, cell extracts were diluted in assay
buffer (20 mM Tris-HCl pH 7.5, 60 mM NaCl, 1 mM DTT,
1 mM EDTA and 7.5 mM MgCl2) and incubated at 30uC for 10
minutes with ss- or dsDNA substrate. The reaction was quenched
by addition of 50 ml salmon DNA and 500 ml of 5% TCA
following centrifugation at 14,000 rpm for 10 minutes at 4uC. The
supernatant was analyzed by liquid scintillation counting. Exper-
iments to monitor residual UDG activity in cell extracts were
performed by incubating cell extracts with the UNG inhibitor Ugi
on ice for 15 minutes prior to addition of substrate.
Genomic 8-oxodG Analysis
Genomic DNA was isolated using the DNeasyH Blood and
Tissue kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The kit’s elution buffer contains EDTA, which
inhibits nucleases during sample preparation for 8-oxo-dG
measurement, so the final elution step was performed using
150 ml water instead of the provided elution buffer. The DNA was
then enzymatically hydrolyzed to deoxynucleosides. To this end,
0.5 mg DNA was added to 40 ml of 100 mM NH4HCO3, pH 7.6,
1 mM CaCl3, 10 mM MgCl2, 1 U recombinant DNase I (Roche),
0.2 mU phosphodiesterase I from Crotalus adamanteus venom
(Sigma-Aldrich), 0.1 U alkaline phosphatase from bovine intestinal
mucosa (Sigma-Aldrich), 1.25 pmol [15N5]8-oxodG (Cambridge
Isotope Laboratories) and incubated at 37 uC for 6 h. To
precipitate contaminants that could potentially clog the HPLC
column, five volumes of ice-cold methanol were added to the
samples, mixed by vortexing, and centrifuged at 16,100 x g for
20 min at 4uC. The supernatants were transferred to new tubes
and vacuum centrifuged at room temperature until dry. The
resulting pellets were dissolved in 25 ml 5% methanol. Liquid
chromatography/tandem mass spectrometric analysis was per-
formed using an LC-20AD HPLC system (Shimadzu Corporation,
Kyoto, Japan) coupled to an API 5000 triple-quadrupole mass
spectrometer (Applied Biosystems, Carlsbad, CA, USA). The
HPLC column was a Zorbax SB-C18 reverse phase chromatog-
raphy column (2.16150 mm, i.d., 3.5mm, Agilent Technologies,
Santa Clara, CA, USA), protected with a Zorbax Reliance guard-
column (4.6 mm612.5 mm, Agilent Technologies) and the
injection volume was 20 ml. The gradient used consisted of solvent
A (water, 0.1% formic acid) and B (methanol, 0.1% formic acid)
starting at 5% B for 0.5 min, ramping to 90% B over 6 min,
holding at 90% B for 1.5 min and re-equilibrating with 5% B for
5 min at a flow rate of 300 ml/min. Mass spectrometric detection
was performed using positive electrospray ionization in multiple
reaction monitoring mode, monitoring the mass transitions 284.1/
168.2 and 289.2/173.1 for 8-oxodG and [15N5]8-oxodG, respec-
tively.
Comet Assay
Cells (1 million cells/mL RPMI medium) were treated with
different doses of Melphalan (50 mM and 100 mM) or vehicle
control (acidified ethanol) for 6 h. The cells were harvested by
centrifugation, embedded in 1% low-melt agar (LMA) and
mounted on microscope slides. The embedded cells were lysed
overnight at 4uC in lysis solution, treated 30 min in alkaline
running buffer (pH.13.3) and subjected to electrophoresis as
described [79]. DNA was visualized by ethidium bromide, and
100 comets were randomly selected and evaluated using Komet
5.0 imaging software (Andor Technology).
Immunofluorescence
Cells were treated with 25 mM Melphalan for different time
points and then fixed in freshly prepared 4% paraformaldehyde
for 10 minutes on ice prior to addition of cold methanol (220uC).
After incubation for 20 minutes at 220uC, cells were washed three
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times with 2% FCS in PBS and incubated with anti-c-H2AX
rabbit polyclonal (ab11174, Abcam, 1:200 dilution) and anti-NFkB
p65 mouse monoclonal antibodies (sc-80086, Santa Cruz, 1:200
dilution) following overnight incubation at 4uC. Anti-NFkB p65
mouse monoclonal antibody was chosen as control for cytoplasmic
staining, since the portion of NFkB present in the cytoplasm is
easily visualized. Cells were then incubated with Alexa Fluor
647 goat anti–rabbit and 532 goat anti-mouse secondary antibod-
ies (Invitrogen, 1:4000 dilution) for 1 h at 37uC. Immunofluores-
cence data were acquired in a laser-scanning microscope (LSM
510 Meta; Carl Zeiss) equipped with a Plan Apochromat
6361.4 NA oil immersion objective and images were analyzed
using LSM 510 software (Carl Zeiss). No image processing except
from contrast and intensity adjustments were performed.
Supporting Information
Figure S1 Intracellular level of ROS was detected by
flow cytometry using 5-(and-6)-carboxy-29,79-dichlorodi-
hydrofluorescein diacetate (carboxy-H2DCFDA, Molec-
ular Probes) according to the manufacturer’s protocol.
Briefly, cells (16106 cells/mL) were washed with PBS and
incubated in PBS buffer containing 10 uM dye for 30 min at
37uC. H2DCFDA-stained cells were returned to growth medium
and treated with 50 uM Melphalan. Flow cytometry analysis was
performed after 6 hours of incubation, at 488 nm excitation and
530 nm emission. Parallel treatment of cells with the oxidizing
agent tert-butyl hydroperoxide (TBHP, Sigma) was included as a
positive control for oxidative stress in the assay.
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